Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-19-059645
Filing Date
2019-11-04
Accepted
2019-11-04 19:04:44
Documents
1
Period of Report
2019-11-04

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm1921748d1_4.html 4  
1 OWNERSHIP DOCUMENT tm1921748d1_4.xml 4 7155
  Complete submission text file 0001104659-19-059645.txt   8717
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

EIN.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 40 BROAD STREET, SUITE 201 BOSTON MA 02109
Business Address 40 BROAD STREET, SUITE 201 BOSTON MA 02109 (857) 254-9492
Vida Ventures, LLC (Reporting) CIK: 0001724489 (see all company filings)

State of Incorp.: NV
Type: 4 | Act: 34 | File No.: 001-39112 | Film No.: 191191135